lower bands is liver and visceral-fat reduction, not additional weight-loss
Ebaa Al Ozairi Real-world data from the Dasman Diabetes Institute in Kuwait published in Diabetes, Obesity and Metabolism examined changes in body weight, HbA1c and other cardiometabolic factors for adults with overweight and type 1 diabetes who were prescribed liraglutide (Saxenda/Victoza, Novo Nordisk), semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly)
If GLP-1 and GIP analog use is to become mainstream in India, the next major wave has to come from physician prescribers beyond the specialist core
[29] Individual tolerance varies, and gradual introduction is advisable to assess personal response
The kidneys remove waste and extra fluids from the body
For some, GLP-1s provide a path forward when everything else has failed